News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,318 Results
Type
Article (39122)
Company Profile (282)
Press Release (647914)
Section
Business (203892)
Career Advice (1994)
Deals (35369)
Drug Delivery (89)
Drug Development (80838)
Employer Resources (168)
FDA (16096)
Job Trends (14806)
News (344617)
Policy (32449)
Tag
Academia (2530)
Alliances (49156)
Alzheimer's disease (1250)
Approvals (16032)
Artificial intelligence (143)
Bankruptcy (352)
Best Places to Work (11569)
Biotechnology (201)
Breast cancer (186)
Cancer (1323)
Cardiovascular disease (106)
Career advice (1662)
Cell therapy (269)
Clinical research (64588)
Collaboration (442)
Compensation (245)
COVID-19 (2540)
C-suite (106)
Data (1358)
Diabetes (163)
Diagnostics (6166)
Earnings (84872)
Employer resources (146)
Events (109926)
Executive appointments (364)
FDA (16725)
Funding (408)
Gene therapy (192)
GLP-1 (590)
Government (4331)
Healthcare (18683)
Infectious disease (2629)
Inflammatory bowel disease (110)
Interviews (309)
IPO (16328)
Job creations (3625)
Job search strategy (1418)
Layoffs (416)
Legal (7858)
Lung cancer (186)
Manufacturing (194)
Medical device (13205)
Medtech (13210)
Mergers & acquisitions (19172)
Metabolic disorders (431)
Neuroscience (1561)
NextGen Class of 2024 (6500)
Non-profit (4466)
Northern California (1638)
Obesity (250)
Opinion (180)
Patents (114)
People (56399)
Phase I (20085)
Phase II (28442)
Phase III (21209)
Pipeline (503)
Postmarket research (2560)
Preclinical (8541)
Radiopharmaceuticals (236)
Rare diseases (252)
Real estate (5890)
Regulatory (21623)
Research institute (2309)
Resumes & cover letters (349)
Southern California (1422)
Startups (3562)
United States (14733)
Vaccines (560)
Weight loss (175)
Date
Today (91)
Last 7 days (677)
Last 30 days (2727)
Last 365 days (35293)
2024 (34423)
2023 (40076)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (194)
Asia (37228)
Australia (6077)
California (3682)
Canada (1409)
China (290)
Colorado (167)
Connecticut (170)
Europe (79734)
Florida (513)
Georgia (130)
Illinois (372)
Indiana (218)
Kansas (96)
Maryland (614)
Massachusetts (2880)
Michigan (169)
Minnesota (285)
New Jersey (1062)
New York (1047)
North Carolina (732)
Northern California (1638)
Ohio (144)
Pennsylvania (901)
South America (1091)
Southern California (1422)
Texas (529)
Utah (105)
Washington State (391)
687,318 Results for "oravax inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com) today announced that its subsidiary, Oravax Medical Inc., reported positive preliminary data from its Phase 1 trial of an oral Covid-19 vaccine candidate.
October 7, 2022
·
6 min read
Pharm Country
Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia
Oramed Pharmaceuticals Inc. announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax’s oral COVID-19 vaccine, currently in development.
December 29, 2021
·
6 min read
Pharm Country
Oramed Provides Update on Oravax: Oral Vaccine Maker Gets IRB Approval for Clinical Trial
Oramed Pharmaceuticals Inc. today announced several updates for its majority-owned company Oravax Medical Inc.
July 21, 2021
·
7 min read
Business
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia
MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today that its investment company Oravax Medical Inc. (“Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (“Oramed”), has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company.
December 29, 2021
·
6 min read
Drug Development
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
Oravax’s oral vaccine targets three surface proteins, making it potentially more effective against current and future variants.
December 14, 2021
·
5 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Business
Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America
Oramed today announced the formation of a 50/50 joint venture between Genomma Lab and Oramed’s majority-owned subsidiary Oravax Medical Inc.
November 18, 2021
·
8 min read
Drug Development
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
MyMD Pharmaceuticals, Inc. reported that its subsidiary Oravax Medical Inc., partially owned with its majority partner Oramed Pharmaceuticals Inc., is preparing to commence clinical trials for its oral COVID-19 vaccine, first in Israel, then in additional clinical sites internationally.
August 10, 2021
·
5 min read
Press Releases
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
·
19 min read
Drug Development
Oramed Announces Oravax’s Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial
Oramed Pharmaceuticals Inc. today announced that its majority-owned subsidiary, Oravax Medical Inc. ( www.ora-vax.com ), has received clearance from the South African Health Products Regulatory Authority to commence patient enrollment in a first in human, Phase 1 clinical trial, for its oral COVID-19 vaccine and preparations to begin the trials are now underway.
October 29, 2021
·
5 min read
1 of 68,732
Next
